Korean Academy of Science and Technology

South Korea's CD BIO Seeks Clinical Trial, FDA Registration for Its VOCs Biosensing Kit That Detects Early Stage Lung and Other Cancers With Simple Breathing Test

Retrieved on: 
Monday, September 5, 2022
Lung cancer, Korean Academy of Science and Technology, CEO, Technology, Cancer, CD, ILRS, ATCS, GLOBE, International, FDA, LLC, Clinical trial, U.S. FDA, Review, Medical device, Pharmaceutical industry

They have plans to submit the device for U.S. FDA approval and conduct further clinical trials.

Key Points: 
  • They have plans to submit the device for U.S. FDA approval and conduct further clinical trials.
  • To reduce the death rate that is increasing due to cancer, Korean company CD BIO's CEO, Baek Kyung-jin, has developed a diagnostic device VOCs Biosensing Kit that detects lung cancer and various cancers at an early stage with a simple breathing test.
  • ILRS and ATCS are collaborating, acting as U.S. agents for CD BIO, overseeing all aspects of international marketing.
  • The clinical trial on the effectiveness of detecting lung cancer and various cancers at an early stage with a simple breathing test was successful, and the thesis presentation was conducted.

Meditation Meets Education, 2021 Seoul Relax Week Meditation Conference Is Held 

Retrieved on: 
Thursday, November 4, 2021
Education, Mental Health, Health, Consumer, Children, Other Education, Social, Curriculum, Amy, Public policy, Mind Games (John Lennon album), Communication, Catholic higher education, COVID-19, Multimedia, Dongguk University, Research, SEE, World Future Society, Meditation, Character education, Mental health, Friends, Institute, Mindfulness, Department, Jogye Order, Shin, Korean Academy of Science and Technology, PayPal, Infant, Engineering, Psychiatry, Adolescence, Culture, Student, MSC, University, Buddhism, Neuropsychiatry, Kwak, University of North Carolina, Empathy, Conference, MBSR, Kweon Kab-yong, Jeju National University, Teahouse, Pharmaceutical industry, Management, Toy

View the full release here: https://www.businesswire.com/news/home/20211104005565/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20211104005565/en/
    With the topic of Mindfulness in Education, the 2021 Meditation Conference will be held from November 5 to 7 as part of the 2021 Seoul Relax Week.
  • To propose and highlight meditation education as public policy, the 2021 Meditation Conference will be held over 3 days from November 5th to November 7th as part of the 2021 Seoul Relax Week .
  • The topic of the 2021 Seoul Relax Week Meditation Conference is Mindfulness in Education.
  • Meanwhile, 2021 Seoul Relax Week is being held all over Seoul and through the online homepage under the topic of Mindfulness Through Meditation.

OliX Pharmaceuticals Announces Results from Preclinical Study of NASH Therapeutic Candidate

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, RNA, Biology, Biochemistry, Gene expression, Molecular biology, Small interfering RNA, RNA interference, N-Acetylgalactosamine

SUWON, Republic of Korea, Aug. 04, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today presented preclinical data on OLX702A, an investigational therapeutic for the treatment of nonalcoholic steatohepatitis (NASH), at the 48th Korean Academy of Science and Technology (KAST) International Symposium. In the study, OLX702A reversed tissue damage in the liver in a mouse model of NASH.

Key Points: 
  • In the study, OLX702A reversed tissue damage in the liver in a mouse model of NASH.
  • OLX702A is a GalNAc-conjugated asymmetric siRNA (asiRNA) that targets a novel gene which is validated as a NASH-related target based on a genome-wide association study (GWAS).
  • We look forward to progressing development of OLX702A based on these encouraging preclinical data, said Dong Ki Lee, Ph.D., founder and chief executive officer of OliX Pharmaceuticals.
  • OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.